Novo Nordisk (NVO) stopped the trial on the progression of renal impairment for people with Type 2 Diabetes and chronic kidney disease after Ozempic showed success in the study. George Tsilis discusses Ozempic’s impact on two other healthcare stocks Davita (DVA) and Baxter (BAX). Tune in to find out more about the stock market today.